<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="3306">
  <stage>Registered</stage>
  <submitdate>16/09/2011</submitdate>
  <approvaldate>16/09/2011</approvaldate>
  <nctid>NCT01441505</nctid>
  <trial_identification>
    <studytitle>A Study of Ketamine as an Antidepressant</studytitle>
    <scientifictitle>A Study of Ketamine as an Antidepressant</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>HREC 10409</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Major Depressive Episode</healthcondition>
    <conditioncode>
      <conditioncode1>Mental Health</conditioncode1>
      <conditioncode2>Depression</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Ketamine
Treatment: drugs - Saline or Midazolam (active placebo)

Treatment: drugs: Ketamine
Ketamine IV, IM, or SC will be administered in Phase I and II

Treatment: drugs: Saline or Midazolam (active placebo)
Saline, or midazolam 0.01mg/kg will be administered in Phase I

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Change from baseline on depression rating scales</outcome>
      <timepoint>Before, 4 hours after, and 24 hours after ketamine session</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Psychiatric side effects (BPRS, CADSS) and memory tests</outcome>
      <timepoint>Cognitive battery done before and after 3 weeks; side effects measured immediately before and 4 hours after each ketamine session in both phases.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Satisfy DSM-IV-TR criteria for Major Depressive Episode

          -  18 years or over

          -  Able to give informed consent</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Diagnosis of schizophrenia, schizoaffective disorder, rapid cycling bipolar disorder,
             or current psychotic symptoms

          -  Known sensitivity or contraindication to ketamine

          -  Recent drug abuse

          -  Pregnant</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Crossover</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2 />
    <masking3>The people assessing the outcomes</masking3>
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>1/09/2011</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>42</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Unknown status</recruitmentstatus>
    <anticipatedlastvisitdate>1/12/2014</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW</recruitmentstate>
    <hospital>Wesley Hospital - Kogarah</hospital>
    <postcode>2217 - Kogarah</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other</primarysponsortype>
    <primarysponsorname>The University of New South Wales</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>Wesley Hospital, Kogarah</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Recently, interest has emerged in the use of ketamine as an antidepressant. Recent
      placebo-controlled clinical trials administering a single dose and an open label trial giving
      repeated doses shown that ketamine is markedly superior to placebo at reducing depression,
      including in treatment-resistant patients, and that its antidepressant effects have a very
      rapid onset.

      This clinical study consists of two phases. In Phase I, participants who satisfy inclusion
      criteria will receive ketamine at variable doses (0.1mg/kg-0.5mg/kg) or a placebo (saline, or
      0.01mg/kg midazolam) once a week over up to 6 weeks. If participants qualify for Phase II,
      they will receive repeated sessions of ketamine at variable doses over three weeks. During
      both phases, mood, psychiatric, and neuropsychological outcomes will be measured.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01441505</trialwebsite>
    <publication>aan het Rot M, Collins KA, Murrough JW, Perez AM, Reich DL, Charney DS, Mathew SJ. Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression. Biol Psychiatry. 2010 Jan 15;67(2):139-45. doi: 10.1016/j.biopsych.2009.08.038.
Berman RM, Cappiello A, Anand A, Oren DA, Heninger GR, Charney DS, Krystal JH. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry. 2000 Feb 15;47(4):351-4.
Diazgranados N, Ibrahim L, Brutsche NE, Newberg A, Kronstein P, Khalife S, Kammerer WA, Quezado Z, Luckenbaugh DA, Salvadore G, Machado-Vieira R, Manji HK, Zarate CA Jr. A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression. Arch Gen Psychiatry. 2010 Aug;67(8):793-802. doi: 10.1001/archgenpsychiatry.2010.90.
Larkin GL, Beautrais AL. A preliminary naturalistic study of low-dose ketamine for depression and suicide ideation in the emergency department. Int J Neuropsychopharmacol. 2011 Sep;14(8):1127-31. doi: 10.1017/S1461145711000629. Epub 2011 May 5.
Zarate CA Jr, Singh JB, Carlson PJ, Brutsche NE, Ameli R, Luckenbaugh DA, Charney DS, Manji HK. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry. 2006 Aug;63(8):856-64.
</publication>
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Colleen K Loo, MB BS FRANZCP MD</name>
      <address>University of New South Wales</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name>Angelo Alonzo</name>
      <address />
      <phone>61 02 9382 3720</phone>
      <fax />
      <email>TMSandDCS@unsw.edu.au</email>
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>